Hyphens Pharma International Reports First Quarter 2024 Earnings
Singapore Shares Drop in Red Despite Global Rally; Biolidics Surges 20% on Wider Losses in Q1
Singapore's Straits Times Index slipped into the red zone on Wednesday, despite an overnight global rally following US inflation data that topped expectations. During the day, the benchmark Singapore
Hyphens Pharma's Q1 Net Profit Nearly Doubles on Broad-Based Sales Growth; Stock Climbs 6%
Hyphens Pharma International (SGX:1J5) nearly doubled its net profit in the first quarter, thanks to improved sales from all segments, especially in the specialty pharma principals unit, according to
Hyphens Pharma Reports Soaring Q1 Profits
Investors in Hyphens Pharma International (Catalist:1J5) Have Seen Favorable Returns of 75% Over the Past Five Years
Hyphens Pharma's Attributable Profit Narrows in 2023
Hyphens Pharma (SGX:1J5) booked a lower attributable profit to equity holders of SG$8.6 million for the year ended Dec. 31, 2023, compared with SG$11.4 million in the year-ago period, according to a f
Huationg Global CEO Increases Interest to 7.75%
Huationg Global CEO increases interest to 7.75%INSTITUTIONS were net buyers of Singapore stocks over the four trading sessions until Apr 4 inclusive, with S$49 million of net institutional inflow, as
Hyphens Pharma Buys Back Shares
Hyphens Pharma International (SGX:1J5) bought back 471,200 shares in the open market on Tuesday, its first purchase since the board approved a buyback program of up to 30.9 million shares last year, a
CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.35 From SG$0.32, Keeps at Add
02:34 AM EDT, 03/15/2024 (MT Newswires) -- CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.35 From SG$0.32, Keeps at Add Price (SGD): S$0.29, Change: S$0.00, Percent Change: 0.00%
Hyphens Pharma Obtains License to MC2's Psoriasis Cream
Hyphens Pharma International (SGX:1J5) obtained an exclusive license to register and commercialize MC2 Therapeutics' Wynzora plaque psoriasis cream in all 10 member countries of the Association of Sou
Hyphens Pharma Licenses Wynzora® Cream for ASEAN Countries From MC2 Therapeutics
Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading...
Hyphens Pharma International Full Year 2023 Earnings: Beats Expectations
Hyphens Pharma International Grants Nearly 6 Million Shares Under Performance Share Plan
Hyphens Pharma International (SGX:1J5) granted a total of 5,854,418 shares to employees under its performance share plan on Friday. Of the total, 2,137,118 shares were granted to Lim See Wah, the comp
CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.32 From SG$0.34, Keeps at Add
05:14 AM EST, 11/28/2023 (MT Newswires) -- CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.32 From SG$0.34, Keeps at Add Price (SGD): S$0.28, Change: S$0.00, Percent Change: -1.79%
Hyphens Pharma Unit Completes Purchase of First Tranche of Remaining Ardence Pharma Stake
Hyphens Pharma International's (SGX:1J5) Hyphens Pharma subsidiary has completed the previously announced purchase of a 23% stake in Malaysia's Ardence Pharma, according to a Wednesday disclosure. The
Hyphens Pharma to Acquire Remaining 58% Stake in Ardence Pharma
Hyphens Pharma International (SGX:1J5), via its unit Hyphens Pharma, is acquiring the remaining 58% stake in Ardence Pharma in three tranches. Under first tranche, the pharmaceutical company will acqu
Is There An Opportunity With Hyphens Pharma International Limited's (Catalist:1J5) 44% Undervaluation?
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia
Hyphens Pharma International (SGX:1J5) said its subsidiary Hyphens Pharma will distribute and sell Daewoong Pharmaceutical's (KRX:069620) botulinum toxin formulation, Nabota, in Malaysia. The Nabota b
Do Hyphens Pharma International's (Catalist:1J5) Earnings Warrant Your Attention?
Hyphens Pharma Names CFO
Hyphens Pharma International (SGX:1J5) appointed Zhang Yufan as its chief financial officer effective June 12, according to a Monday filing. Prior to joining the company, Zhang was previously CFO of T
No Data